Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects
about
Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled studyPitfalls associated with the therapeutic reference pricing practice of asthma medication.Discriminating measures of bronchodilator drug efficacy and potency.Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.Differences in the pharmacodynamics of budesonide/formoterol and salmeterol/fluticasone reflect differences in their therapeutic usefulness in asthma.Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trialIndacaterol, A Novel Once Daily Inhaled beta2-Adrenoreceptor Agonist.Third-generation long-acting β₂-adrenoceptor agonists: medicinal chemistry strategies employed in the identification of once-daily inhaled β₂-adrenoceptor agonists.Gaining the Upper Hand on Pulmonary Drug Delivery.Comparison of systemic pharmacodynamic effects of two combination pressurized metered dose inhalers that deliver salmeterol and fluticasone propionate.A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroid.Pharmacodynamic Studies to Demonstrate Bioequivalence of Oral Inhalation Products.The preclinical toxicology of salmeterol hydroxynaphthoate.Bronchodilatation effects of a small volume spacer used with a metered-dose inhaler.Salbutamol effects on systemic potassium dynamics during and following intense continuous and intermittent exercise.Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD.
P2860
Q33839737-FD255FF4-8195-47AB-A563-B7F81524D6FDQ33919207-2EBDB704-9788-44AC-88E8-96756E1E4159Q34346665-71B4D55A-DD2D-491A-82D0-4147855AE9BDQ34371771-EDFD8192-925F-4321-95B1-5AE1B25CF1DEQ35533937-CA708FEE-8803-41C3-BFD9-1746A23AC4AEQ35627925-DCA1C592-48E8-413C-93DF-DE47664C14F3Q37362634-2031EF87-80FC-457D-9A82-3D8FBC3EE7B5Q37404474-CBAD18C2-F5B7-4CCB-987E-21AAE7AF4C41Q37487619-7594092B-EEBE-487D-B245-C7D17A23D1DAQ37937552-33C41442-03A2-45F0-9F82-A287E3E2A129Q38240156-B2E45576-226B-496E-898C-0CE654E88F9EQ38719927-A8ACE63E-C133-4BE0-8F75-929B2C58A30DQ42110251-0C993BDD-C6F8-4F2D-9C11-CE1745C5D9D4Q42593035-06231E73-B455-471D-978A-4FB4885F9FABQ43134820-1664D007-4371-4B46-88F7-12B74C4D84B1Q43281499-9A7064EA-818D-4D0C-BA88-5A9CCCE6707DQ47374059-CC14E125-FB37-4ABA-87F6-BEC0EFF2495CQ47966525-8E6BED6D-5B52-421A-AC82-1C9F9DD1C925
P2860
Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Time course and relative dose ...... salbutamol in healthy subjects
@ast
Time course and relative dose ...... salbutamol in healthy subjects
@en
type
label
Time course and relative dose ...... salbutamol in healthy subjects
@ast
Time course and relative dose ...... salbutamol in healthy subjects
@en
prefLabel
Time course and relative dose ...... salbutamol in healthy subjects
@ast
Time course and relative dose ...... salbutamol in healthy subjects
@en
P2860
P356
P1433
P1476
Time course and relative dose ...... salbutamol in healthy subjects
@en
P2093
Bennett JA
Tattersfield AE
P2860
P304
P356
10.1136/THX.52.5.458
P407
P577
1997-05-01T00:00:00Z